Moderna Inc. ($MRNA) Stock Forecast: Down 6.1% Today

What is Moderna Inc.?

A biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines, had a bearish movement in the stock market today as investors speculate on the upcoming quarterly earnings release and insider activities.

Why is Moderna Inc. going down?

MRNA stock is down 6.1% on Feb 6, 2026 15:16

• The stock experienced a bearish movement, possibly due to the anticipation of its upcoming quarterly earnings projecting a loss per share and lower revenue than expected.
• Recent insider selling activity might have also contributed to the negative sentiment surrounding the stock.
• The launch of leveraged ETFs tied to the company's share prices could have amplified the downward pressure on the stock as traders adjusted their positions based on market volatility and risk factors associated with leveraged products.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna (MRNA) to Release Quarterly Earnings on Friday

Moderna (MRNA) is expected to report its Q4 2025 earnings before the market opens on Friday, February 13th, with analysts projecting a loss of ($2.79) per share on revenue of $611.14 million. The company's stock was down approximately 4.4% at market open, with a consensus "Reduce" rating and an average price target of $28.77 from analysts. Insider activity shows a director recently sold a significant number of shares, and institutional investors have been adjusting their holdings.

https://www.marketbeat.com/instant-alerts/moderna-mrna-to-release-quarterly-earnings-on-friday-2026-02-06/

The Truth About Telix Pharmaceuticals: Is This Quiet Biotech About To Go Full Viral?

Telix Pharmaceuticals is gaining attention in biotech circles due to its focus on targeted radiopharmaceuticals for cancer, with existing commercial products generating revenue. While not a mainstream meme stock, it's considered a "must-watch" by early investors and biotech analysts. The article evaluates Telix's potential against its risks, categorizing it as a high-risk, high-reward investment for tolerant investors due to its innovative product, revenue stream, and market volatility.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-telix-pharmaceuticals-is-this-quiet-biotech-about-to-go/68556497

Defiance adds single stock ETFs tied to Zeta Global, Moderna

Defiance ETFs has launched two new single-stock leveraged ETFs, the Defiance Daily Target 2X Long ZETA ETF and the Defiance Daily Target 2X Long MRNA ETF. These products offer traders amplified, short-term exposure, providing twice the daily percentage change of Zeta Global Holdings Corp and Moderna Inc's share prices. They are intended for investors familiar with the risks associated with daily leveraged products.

https://www.structuredretailproducts.com/insights/82474/defiance-adds-leveraged-single-stock-etfs-tied-to-zeta-global-moderna

Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?

Neurocrine Biosciences is set to report its fourth-quarter 2025 results on February 11, with analysts expecting revenues of $784.42 million and EPS of $2.27. The company's growth is primarily driven by strong sales of its marketed drugs, Ingrezza and Crenessity, and royalty income, all of which are expected to contribute to a year-over-year revenue jump. Investors will also be keen on updates regarding its late-stage pipeline, including direclidine for schizophrenia and osavampator for major depressive disorder.

https://finviz.com/news/301570/neurocrine-biosciences-to-report-q4-earnings-whats-in-the-cards

Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?

Neurocrine Biosciences (NBIX) is set to report its fourth-quarter 2025 results on Feb. 11, with investors focusing on the sales performance of Ingrezza and Crenessity, as well as pipeline updates. The company expects revenue growth driven by increased sales of marketed drugs and higher collaboration revenues. Despite a mixed earnings surprise history, NBIX has an Earnings ESP of +1.90%, though it currently holds a Zacks Rank #4 (Sell).

https://www.tradingview.com/news/zacks:8ffe42aec094b:0-neurocrine-biosciences-to-report-q4-earnings-what-s-in-the-cards/

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.0% Today

Moderna Inc. Price History

30.00.2026 - MRNA Stock was down 5.4%

• A recent partnership for the development of mRNA-3927 for propionic acidemia highlights Moderna's dedication to broadening its portfolio beyond vaccines.
• The appointment of Dr. David Berman as Chief Development Officer brings valuable expertise in immunotherapy, potentially indicating a shift towards advancing clinical-stage therapies.
• Despite recent positive developments, concerns over financial pressures and an ambitious profitability target set for 2028 have led to a bearish market reaction.
• Investors may be cautious about the leadership transition from Dr. Jacqueline Miller to Dr. David Berman, as such changes can introduce uncertainties impacting stock performance.

30.00.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement following the announcement of the departure of its chief medical officer amidst other executive departures within the company.
• The appointment of Dr. David Berman as the new Chief Development Officer was not enough to offset the negative sentiment, as investors may be concerned about the leadership changes and potential impact on the company's future direction.
• The partnership with Recordati to develop an mRNA therapy for a rare metabolic disorder was a positive development, but it seems the market focused more on the internal leadership changes at Moderna.
• The overall market reaction suggests that investors are closely monitoring Moderna's executive team transitions and the company's ability to maintain its innovative edge in mRNA technology amidst leadership shake-ups.

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

06.01.2026 - MRNA Stock was down 6.1%

• The stock experienced a bearish movement, possibly due to the anticipation of its upcoming quarterly earnings projecting a loss per share and lower revenue than expected.
• Recent insider selling activity might have also contributed to the negative sentiment surrounding the stock.
• The launch of leveraged ETFs tied to the company's share prices could have amplified the downward pressure on the stock as traders adjusted their positions based on market volatility and risk factors associated with leveraged products.

28.00.2026 - MRNA Stock was down 8.4%

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

05.01.2026 - MRNA Stock was down 6.2%

• Moderna's stock experienced a bearish movement possibly due to legal uncertainties surrounding its mRNA vaccine technology in the Arbutus v. Moderna patent infringement case.
• The market may have reacted negatively to the summary judgment rulings issued by Judge Wolson, which could impact Moderna's vaccine sales and ongoing legal battles.
• Despite advancements in oncology and promising clinical trial results in the industry, the specific legal challenges faced by Moderna might have overshadowed positive developments in the broader healthcare sector.
• Investors might be cautious about the implications of the legal proceedings on Moderna's revenue and market position, leading to the bearish movement in the stock price.

02.01.2026 - MRNA Stock was up 5.3%

• Moderna's upward momentum can be associated with the encouraging insights shared during the 44th Annual J.P. Morgan Healthcare Conference. The company emphasized its strategic business expansion, progress in product development, and anticipated financial performance over the upcoming years.
• The market responded positively to Moderna's detailed three-year business plan revealed during its Analyst Day. The plan included forecasts for revenue growth, expansion of its vaccine portfolio, and a heightened focus on oncology and rare disease treatments.
• Investors seemingly responded to Moderna's growth potential, despite concerns raised regarding declining revenue and projected performance compared to industry standards. The optimistic narrative presented by Moderna during recent conferences likely overshadowed these underlying challenges in the near term.

03.01.2026 - MRNA Stock was down 7.0%

• Despite a positive performance over the past year and year-to-date, Moderna's stock witnessed a bearish movement today. This comes in light of successful partnerships and promising experimental vaccines.
• The robust financial results and pipeline progress of Merck & Co. may have diverted investor attention from Moderna, impacting MRNA's stock adversely.
• Moderna's announcement of an upcoming webinar on decision intelligence for an autonomous cold chain underscores its dedication to innovation. However, this development might not have been sufficient to counter the prevailing market sentiment affecting MRNA's stock.
• The FDA's recent request for monitoring myocarditis in a new COVID antibody trial possibly added to market uncertainty. This factor could have influenced the bearish movement in Moderna's stock observed today.

29.00.2026 - MRNA Stock was up 5.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding its ongoing developments and potential in the healthcare sector.
• The reduction in stake by Federated Hermes Inc. and director Noubar Afeyan might have initially raised concerns, but the market likely focused more on the broader positive outlook for the company.
• The strong performance of healthcare stocks in the past month, including Moderna, reflects investor confidence in the sector, further boosting MRNA's upward momentum.
• With the focus on NLRP3 inhibitors by other companies like Eli Lilly and BioAge Labs, the overall excitement and advancements in healthcare innovation could have positively influenced Moderna's stock performance.

29.00.2026 - MRNA Stock was up 5.7%

• Moderna's stock soared as investors exhibited confidence in the company's innovative mRNA technology and its promising prospects for growth.
• The decision by Federated Hermes Inc. and director Noubar Afeyan to reduce their stake may have sparked some initial market uncertainty, but the prevailing sentiment leaned towards positivity.
• The stock's remarkable performance could also be linked to its inclusion in the top healthcare stocks list, showcasing its resilience and growth potential in the sector.
• The increased market interest in healthcare stocks, evident from the leading ETFs and the focus on NLRP3 inhibitors by other entities, likely contributed to the further elevation of Moderna's stock price.